Bcl-2-regulated apoptosis: mechanism and therapeutic potential

Current Opinion in Immunology

Volumn 19, Issue 5, 2007, Pages 488-496

  Adams, Jerry M ^a   Cory, Suzanne ^a  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; BH3 PROTEIN; GX 15 070; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PYRROLE DERIVATIVE; UNCLASSIFIED DRUG;

APOPTOSIS; AUTOIMMUNITY; AUTOPHAGY; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DRUG MECHANISM; HUMAN; NONHUMAN; PROTEIN INTERACTION; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; AUTOPHAGY; BH3 INTERACTING DOMAIN DEATH AGONIST PROTEIN; BIPHENYL COMPOUNDS; HUMANS; METABOLIC NETWORKS AND PATHWAYS; MITOCHONDRIA; MOLECULAR MIMICRY; NEOPLASMS; NITROPHENOLS; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-BCL-2; SULFONAMIDES;

EID: 34748924281     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coi.2007.05.004     Document Type: Review

References (77)

1. Strasser A. The role of BH3-only proteins in the immune system. Nat Rev Immunol 5 (2005) 189-200. This recent review clearly outlines the physiological roles of the Bcl-2 family and apoptosis, particularly in the immune system.
2. Adams J.M. Ways of dying: multiple pathways to apoptosis. Genes Dev 17 (2003) 2481-2495
3. Shi Y. Mechanical aspects of apoptosome assembly. Curr Opin Cell Biol 18 (2006) 677-684
4. Adams J.M., and Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 26 (2007) 1324-1337. This recent review focuses on the mechanisms by which the Bcl-2 family control apoptosis and their impact on cancer development and therapy.
5. Hinds M.G., and Day C.L. Regulation of apoptosis: uncovering the binding determinants. Curr Opin Struct Biol 15 (2005) 690-699
6. L sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol Cell 8 (2001) 705-711
7. Zong W.X., Lindsten T., Ross A.J., MacGregor G.R., and Thompson C.B. BH3-only proteins that bind pro-survival Bcl-2 family members fail to induce apoptosis in the absence of Bax and Bak. Genes Dev 15 (2001) 1481-1486
8. Danial N.N., and Korsmeyer S.J. Cell death: critical control points. Cell 116 (2004) 205-219
9. Fesik S.W. Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 5 (2005) 876-885. This review outlines different approaches for targeting the apoptotic machinery in cancer therapy.
10. Chen L., Willis S.N., Wei A., Smith B.J., Fletcher J.I., Hinds M.G., Colman P.M., Day C.L., Adams J.M., and Huang D.C.S. Differential targeting of pro-survival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 17 (2005) 393-403. This study revealed the selectivity of BH3 domains in binding the pro-survival proteins (see also Ref. [12,13]) and demonstrated that apoptosis requires neutralization of multiple Bcl-2 homologs.
11. Letai A., Bassik M., Walensky L., Sorcinelli M., Weiler S., and Korsmeyer S. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2 (2002) 183-192
12. •]).
13. Certo M., Moore Vdel G., Nishino M., Wei G., Korsmeyer S., Armstrong S.A., and Letai A. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 9 (2006) 351-365
14. Walensky L.D., Pitter K., Morash J., Oh K.J., Barbuto S., Fisher J., Smith E., Verdine G.L., and Korsmeyer S.J. A stapled BID BH3 helix directly binds and activates BAX. Mol Cell 24 (2006) 199-210. The first quantitative data supporting the idea that certain BH3 peptides, if constrained into an a-helix, may be able to active Bax directly (see also [15]).
15. Oh K.J., Barbuto S., Pitter K., Morash J., Walensky L.D., and Korsmeyer S.J. A membrane-targeted BID BCL-2 homology 3 peptide is sufficient for high potency activation of BAX in vitro. J Biol Chem 281 (2006) 36999-37008
16. Kim H., Rafiuddin-Shah M., Tu H.C., Jeffers J.R., Zambetti G.P., Hsieh J.J., and Cheng E.H. Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies. Nat Cell Biol 8 (2006) 1348-1358. This study provided evidence that sequestration by pro-survival proteins in itself is insufficient to account for the regulation of Bax and Bak and reported further data indicating that Bak is inhibited by the VDAC2, a pore-forming protein in the mitochondrial outer membrane.
17. Cartron P.F., Gallenne T., Bougras G., Gautier F., Manero F., Vusio P., Meflah K., Vallette F.M., and Juin P. The first alpha helix of Bax plays a necessary role in its ligand-induced activation by the BH3-only proteins Bid and PUMA. Mol Cell 16 (2004) 807-818
18. Ming L., Wang P., Bank A., Yu J., and Zhang L. PUMA dissociates Bax and Bcl-XL to induce apoptosis in colon cancer cells. J Biol Chem 281 (2006) 16034-16042
19. ••,21]).
20. ••,21]).
21. Uren R.T., Dewson G., Chen L., Adams J.M., Huang D.C.S., and Kluck R.M. Mitochondrial permeabilization relies on BH3 ligands engaging multiple pro-survival Bcl-2 relatives rather than Bak. J Cell Biol 177 (2007) 277-287
22. Erlacher M., Laabi V., Manzl C., Bock G., Tzankov A., Haecker G., Strasser A., and Villunger A. Puma cooperates with Bim, the rate-limiting BH3-only protein in cell death during lymphocyte development, in apoptosis induction. J Exp Med 203 (2006) 2939-2951
23. Lindsten T., Ross A.J., King A., Zong W., Rathmell J.C., Shiels H.A., Ulrich E., Waymire K.G., Mahar P., Frauwirth K., et al. The combined functions of proapoptotic Bcl-2 family members Bak and Bax are essential for normal development of multiple tissues. Mol Cell 6 (2000) 1389-1399
24. White E. Mechanisms of apoptosis regulation by viral oncogenes in infection and tumorigenesis. Cell Death Differ 13 (2006) 1371-1377
25. Kvansakul M., Van Delft M.F., Lee E.F., Gulbis J.M., Fairlie W.D., Huang D.C.S., and Colman P.M. A structural viral mimic of pro-survival Bcl-2: a pivotal role for sequestering pro-apoptotic Bax and Bak. Mol Cell 25 (2007) 933-942. The pro-survival function of a viral structural mimic of Bcl-2 is shown to rely upon binding Bax and Bak rather than BH3-only proteins.
26. Kuwana T., Mackey M.R., Perkins G., Ellisman M.H., Latterich M., Schneiter R., Green D.R., and Newmeyer D.D. Bid, Bax, and lipids cooperate to form supramolecular openings in the outer mitochondrial membrane. Cell 111 (2002) 331-342
27. L and Bak, supporting death by default.
28. Cuconati A., Mukherjee C., Perez D., and White E. DNA damage response and MCL-1 destruction initiate apoptosis in adenovirus-infected cells. Genes Dev 17 (2003) 2922-2932
29. Hsu Y.T., and Youle R.J. Nonionic detergents induce dimerization among members of the Bcl-2 family. J Biol Chem 272 (1997) 13829-13834
30. Suzuki M., Youle R.J., and Tjandra N. Structure of Bax: coregulation of dimer formation and intracellular localization. Cell 103 (2000) 645-654
31. Moldoveanu T., Liu Q., Tocilj A., Watson M.H., Shore G., and Gehring K. The x-ray structure of a BAK homodimer reveals an inhibitory zinc binding site. Mol Cell 24 (2006) 677-688
32. Hsu Y.-T., and Youle R.J. Bax in murine thymus is a soluble monomeric protein that displays differential detergent-induced conformations. J Biol Chem 273 (1998) 10777-10783
33. Kim B.J., Ryu S.W., and Song B.J. JNK- and p38 kinase-mediated phosphorylation of Bax leads to its activation, mitochondrial translocation and to apoptosis of human hepatoma HepG2 cells. J Biol Chem 281 (2006) 21256-21265
34. Gardai S.J., Hildeman D.A., Frankel S.K., Whitlock B.B., Frasch S.C., Borregaard N., Marrack P., Bratton D.L., and Henson P.M. Phosphorylation of Bax Ser184 by Akt regulates its activity and apoptosis in neutrophils. J Biol Chem 279 (2004) 21085-21095
35. Walensky L.D., Kung A.L., Escher I., Malia T.J., Barbuto S., Wright R.D., Wagner G., Verdine G.L., and Korsmeyer S.J. Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science 305 (2004) 1466-1470
36. Sadowsky J.D., Schmitt M.A., Lee H.S., Umezawa N., Wang S., Tomita Y., and Gellman S.H. Chimeric (alpha/beta + alpha)-peptide ligands for the BH3-recognition cleft of Bcl-XL: critical role of the molecular scaffold in protein surface recognition. J Am Chem Soc 127 (2005) 11966-11968
37. Sadowsky J.D., Fairlie W.D., Hadley E.B., Lee H.S., Umezawa N., Nikolovska-Coleska Z., Wang S., Huang D.C., Tomita Y., and Gellman S.H. (alpha/beta + alpha)-Peptide antagonists of BH3 domain/Bcl-x(L) recognition: toward general strategies for foldamer-based inhibition of protein-protein interactions. J Am Chem Soc 129 (2007) 139-154
38. Oltersdorf T., Elmore S.W., Shoemaker A.R., Armstrong R.C., Augeri D.J., Belli B.A., Bruncko M., Deckwerth T.L., Dinges J., Hajduk P.J., et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435 (2005) 677-681. This study describing the initial findings with ABT-737 illustrates the therapeutic potential of this new class of potential anti-cancer agents.
39. Konopleva M., Contractor R., Tsao T., Samudio I., Ruvolo P.P., Kitada S., Deng X., Zhai D., Shi Y.-X., Sneed T., et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 10 (2006) 375-388
40. •,53]).
41. Tahir S.K., Yang X., Anderson M.G., Morgan-Lappe S.E., Sarthy A.V., Chen J., Warner R.B., Ng S.C., Fesik S.W., Elmore S.W., et al. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. Cancer Res 67 (2007) 1176-1183
42. •], this study explored how ABT-737 works and ways of enhancing its activity in tumor cells that have substantial Mcl-1.
43. Lin X., Morgan-Lappe S., Huang X., Li L., Zakula D.M., Vernetti L.A., Fesik S.W., and Shen Y. 'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-X(L) inhibitor ABT-737. Oncogene 26 (2007) 3972-3979
44. Del Gaizo Moore V., Brown J.R., Certo M., Love T.M., Novina C.D., and Letai A. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest 117 (2007) 112-121
45. Shoemaker A.R., Oleksijew A., Bauch J., Belli B.A., Borre T., Bruncko M., Deckwirth T., Frost D.J., Jarvis K., Joseph M.K., et al. A small-molecule inhibitor of Bcl-XL potentiates the activity of cytotoxic drugs in vitro and in vivo. Cancer Res 66 (2006) 8731-8739
46. Chauhan D., Velankar M., Brahmandam M., Hideshima T., Podar K., Richardson P., Schlossman R., Ghobrial I., Raje N., Munshi N., et al. A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Oncogene 26 (2007) 2374-2380
47. Kuroda J., Puthalakath H., Cragg M.S., Kelly P.N., Bouillet P., Huang D.C., Kimura S., Ottmann O.G., Druker B.J., Villunger A., et al. Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc Natl Acad Sci U S A 103 (2006) 14907-14912. The cytotoxic activity of imatinib was shown to rely on Bim and Bad but their activity could be replaced by the Bad-like ABT-737, suggesting that co-treatment with imatinib and the BH3 mimetic might enhance efficacy, particularly in patients refractory to imatinib alone.
48. Perez-Galan P., Roue G., Villamor N., Campo E., and Colomer D. The BH3-mimetic GX15-070 synergizes with Bortezomib in Mantle Cell Lymphoma by enhancing Noxa-mediated activation of Bak. Blood 109 (2007) 4441-4449
49. Lum J.J., Bauer D.E., Kong M., Harris M.H., Li C., Lindsten T., and Thompson C.B. Growth factor regulation of autophagy and cell survival in the absence of apoptosis. Cell 120 (2005) 237-248. Hematopoietic cells lacking Bax and Bak, when deprived of cytokine, are shown to survive for an extended period by undergoing autophagy but eventually to succumb to non-apoptotic death.
50. Tsujimoto Y., and Shimizu S. Another way to die: autophagic programmed cell death. Cell Death Differ 12 Suppl. 2 (2005) 1528-1534
51. Qu X., Yu J., Bhagat G., Furuya N., Hibshoosh H., Troxel A., Rosen J., Eskelinen E.L., Mizushima N., Ohsumi Y., et al. Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J Clin Invest 112 (2003) 1809-1820
52. L with the autophagy regulator Beclin-1.
53. Hoyer-Hansen M., Bastholm L., Szyniarowski P., Campanella M., Szabadkai G., Farkas T., Bianchi K., Fehrenbacher N., Elling F., Rizzuto R., et al. Control of macroautophagy by calcium, calmodulin-dependent kinase kinase-beta, and Bcl-2. Mol Cell 25 (2007) 193-205
54. Oberstein A., Jeffrey P., and Shi Y. Crystal structure of the BCL-XL-beclin 1 peptide complex: Beclin 1 is a novel BH3-only protein. J Biol Chem 282 (2007) 13123-13132
55. Shimizu S., Kanaseki T., Mizushima N., Mizuta T., Arakawa-Kobayashi S., Thompson C.B., and Tsujimoto Y. Role of Bcl-2 family proteins in a non-apoptotic programmed cell death dependent on autophagy genes. Nat Cell Biol 6 (2004) 1221-1228. Whereas most studies suggest that Bcl-2 inhibits autophagy, this study reported that, in the presence of cytotoxic drugs, Bcl-2 instead stimulated autophagic cell death.
56. Amaravadi R.K., Yu D., Lum J.J., Bui T., Christophorou M.A., Evan G.I., Thomas-Tikhonenko A., and Thompson C.B. Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. J Clin Invest 117 (2007) 326-336
57. Arnoult D. Mitochondrial fragmentation in apoptosis. Trends Cell Biol 17 (2007) 6-12
58. Karbowski M., Norris K.L., Cleland M.M., Jeong S.Y., and Youle R.J. Role of Bax and Bak in mitochondrial morphogenesis. Nature 443 (2006) 652-658
59. Delivani P., Adrain C., Taylor R.C., Duriez P.J., and Martin S.J. Role for CED-9 and Egl-1 as regulators of mitochondrial fission and fusion dynamics. Mol Cell 21 (2006) 761-773
60. Jagasia R., Grote P., Westermann B., and Conradt B. DRP-1-mediated mitochondrial fragmentation during EGL-1-induced cell death in C. elegans. Nature 433 (2005) 754-760
61. Parone P.A., James D.I., Da Cruz S., Mattenberger Y., Donze O., Barja F., and Martinou J.C. Inhibiting the mitochondrial fission machinery does not prevent bax/bak-dependent apoptosis. Mol Cell Biol 26 (2006) 7397-7408
62. Lakhani S.A., Masud A., Kuida K., Porter Jr. G.A., Booth C.J., Mehal W.Z., Inayat I., and Flavell R.A. Caspases 3 and 7: key mediators of mitochondrial events of apoptosis. Science 311 (2006) 847-851. This study of cells lacking both the major effector caspases unexpectedly revealed that the majority of Bax may translocate to the mitochondrial membrane after caspase activation (see also Ref. [63,64], suggesting that a positive feedback loop operates.
63. Zhu Y., Liu X., Hildeman D., Peyerl F.W., White J., Kushnir E., Kappler J., and Marrack P. Bax does not have to adopt its final form to drive T cell death. J Exp Med 203 (2006) 1147-1152
64. Kepp O., Rajalingam K., Kimmig S., and Rudel T. Bak and Bax are non-redundant during infection- and DNA damage-induced apoptosis. EMBO J 26 (2007) 825-834
65. Oakes S.A., Scorrano L., Opferman J.T., Bassik M.C., Nishino M., Pozzan T., and Korsmeyer S.J. Proapoptotic BAX and BAK regulate the type 1 inositol trisphosphate receptor and calcium leak from the endoplasmic reticulum. Proc Natl Acad Sci U S A 102 (2005) 105-110
66. White C., Li C., Yang J., Petrenko N.B., Madesh M., Thompson C.B., and Foskett J.K. The endoplasmic reticulum gateway to apoptosis by Bcl-X(L) modulation of the InsP3R. Nat Cell Biol 7 (2005) 1021-1028
67. Hetz C., Bernasconi P., Fisher J., Lee A.H., Bassik M.C., Antonsson B., Brandt G.S., Iwakoshi N.N., Schinzel A., Glimcher L.H., et al. Proapoptotic BAX and BAK modulate the unfolded protein response by a direct interaction with IRE1alpha. Science 312 (2006) 572-576
68. Kamer I., Sarig R., Zaltsman Y., Niv H., Oberkovitz G., Regev L., Haimovich G., Lerenthal Y., Marcellus R.C., and Gross A. Proapoptotic BID is an ATM effector in the DNA-damage response. Cell 122 (2005) 593-603
69. Zinkel S.S., Hurov K.E., Ong C., Abtahi F.M., Gross A., and Korsmeyer S.J. A role for proapoptotic BID in the DNA-damage response. Cell 122 (2005) 579-591
70. Kaufmann T., Tai L., Ekert P.G., Huang D.C.S., Norris F., Dixit V.M., and Strasser A. The pro-apoptotic BH3-only protein Bid is dispensable for DNA damage and replicative stress-induced apoptosis and cell cycle arrest. Cell 129 (2007) 423-433
71. Puthalakath H, O'reilly LA, Gunn P, Lee L, Kelly PN, Huntington ND, Hughes PD, Michalak EM, McKimm-Breschkin J, Motoyama N, et al.: Stress-induced apoptosis requires activation of the BH3-only protein Bim by PP2A-mediated de-phosphorylation and CHOP-C/EBP?-mediated transcriptional induction. Cell In Press.
72. Czabotar P.E., Lee E.F., van Delft M.F., Day C.L., Smith B.J., Huang D.C.S., Fairlie W.D., Hinds M.G., and Colman P.M. Structural insights into the degradation of Mcl-1 induced by BH3 domains. PNAS 104 (2007) 6217-6222
73. Lee EF, Czabotar PE, Smith BJ, Deshayes K, Zobel K, Colman PM, Fairlie WD: Crystal structure of ABT-737 completed with Bcl-x(L): implications for selectivity of antagonists of the Bcl-2 family. Cell Death & Differentiation. In Press.
74. Kang MH, Kang YH, Szymanska B, Wilczynska-Kalak U, Sheard MA, Harned T, Lock RB, Reynolds CP: Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo. Blood In Press.
75. Kuroda J, Kimura S, Strasser A, Andreeff M, O'Reilly LA, Ashihara E, Kamitsuji Y, Yokota A, Kawata E, Takeuchi M, et al.: Apoptosis-based dual molecular targeting by INNO-406, a second generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of anti-apoptotic Bcl-2 proteins against Bcr-Abl-positive leukemia. Cell Death & Differentiation. In Press.
76. Maiuri M.C., Le Toumelin G., Criollo A., Rain J.C., Gautier F., Juin P., Tasdemir E., Pierron G., Troulinaki K., Tavernarakis N., et al. Functional and physical interaction between Bcl-X(L) and a BH3-like domain in Beclin-1. Embo J 26 (2007) 2527-2539
77. Mathew R., Kongara S., Beaudoin B., Karp C.M., Bray K., Degenhardt K., Chen G., Jin S., and White E. Autophagy suppresses tumor progression by limiting chromosomal instability. Genes Dev 21 (2007) 1367-1381